Novanta Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-90.1% vs price
Base Case (Median)
-79.0% vs price
Bull Case (75th pct.)
-75.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $14.50 | -91.4% | High (40%) |
| PE Comparable | $39.54 | -76.6% | Medium (25%) |
| Growth Trajectory DCF | $17.11 | -89.9% | Medium (20%) |
| Graham Number | $35.51 | -79.0% | Low (10%) |
| EV/EBITDA | $41.83 | -75.2% | Medium (20%) |
| EV/FCF | $62.47 | -63.0% | Medium (20%) |
| Earnings Power Value | $16.38 | -90.3% | Medium (50%) |
Based on 7 out of 8 methods, NOVT appears overvalued at the current price of $168.75. The base case fair value of $35.51 implies 79.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.